CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...
CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing. The Centers for Medicare & Medicaid Services (CMS) ...
The Centers for Medicare & Medicaid Services (CMS) recently published its Proposed 2026 Physician Fee Schedule Rule (Proposed Rule), with extensive implications for drug pricing, Average Sales Price ...
The Centers for Medicare & Medicaid Services is proposing to decrease payments to hospitals that purchase drugs under the 340B program to align the rate to reflect what providers pay for the ...
Every July, the Centers for Medicare & Medicaid Services (CMS) publishes two proposed rules relating to how it plans to administer the Medicare Part B program for the next calendar year: the physician ...
In order to help ensure the accuracy of Medicare Part B drug payment rates, the US Government Accountability Office (GAO) on Monday urged Congress to require all manufacturers of Part B drugs paid at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results